BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through three segments: Interventional Medicine, Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications. This segment also provides interventional vascular products consisting of EKOS system, an ultrasonic catheter drug delivery device used in the treatment of blood clots; Varithena for the treatment of varicose veins; and PneumRx Coil for the treatment of emphysema, a debilitating lung disease. The Pharmaceuticals segment offers antidote products, such as CroFab for the treatment of crotalid snake envenomations; DigiFab for the treatment of digoxin toxicity; and Voraxaze for high-dose methotrexate toxicity. The Licensing segment provides Zytiga for treatment of prostate cancer; Two-Part Hip Cup; and Lemtrada. The company also manufactures and commercializes therapeutic ultrasound devices, and roxwood systems, as well as develops venous thrombus management devices. The company was formerly known as British Technology Group International plc and changed its name to BTG plc in March 1995. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange LON
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolLON:BTG
CUSIPN/A
Phone+44-20-75750000
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins15.50%
Return on Equity10.80%
Return on Assets8.07%
Miscellaneous
EmployeesN/A
Outstanding Shares386,400,000
Market Cap£2,640.00
BTG (LON:BTG) Frequently Asked Questions
What is BTG's stock symbol?
BTG trades on the London Stock Exchange (LON) under the ticker symbol "BTG."
How were BTG's earnings last quarter?
BTG plc (LON:BTG) released its earnings results on Tuesday, May, 15th. The company reported $32.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $29.80 by $3.10. BTG had a net margin of 15.50% and a return on equity of 10.80%. View BTG's Earnings History.
What price target have analysts set for BTG?
8 brokerages have issued 12-month price objectives for BTG's shares. Their forecasts range from GBX 510 to GBX 900. On average, they anticipate BTG's share price to reach GBX 712.14 in the next twelve months. This suggests a possible upside of 41.7% from the stock's current price. View Analyst Ratings for BTG.
What is the consensus analysts' recommendation for BTG?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BTG in the last year. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
Who are some of BTG's key competitors?
Some companies that are related to BTG include ABLYNX NV/ADR (ABLX), MorphoSys (MPSYY), Abcam (ABC), MorphoSys (MOR), Almirall (LBTSF), Sosei Group (SOLTF), Sirtex Medical (SRX), Genus (GNS), Biotest (BIO), ProMetic Life Sciences (PLI), Genfit (GNFTF), Mesoblast (MSB), Theratechnologies (TH), Mesoblast (MEOBF) and Emerald Health Therapeutics (EMH).
Who are BTG's key executives?
BTG's management team includes the folowing people:
- Dr. Louise Makin, CEO & Exec. Director (Age 57)
- Mr. Duncan Kennedy, Chief Financial Officer
- Dr. Peter Stratford, Chief Technical Officer & Head of Innovation (Age 51)
- Dr. Melanie G. Lee, Chief Scientific Officer (Age 60)
- Mr. Andy Burrows, VP of Corp. & Investor Relations
Has BTG been receiving favorable news coverage?
Press coverage about BTG stock has trended somewhat positive recently, Accern reports. The research firm ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BTG earned a media sentiment score of 0.17 on Accern's scale. They also assigned media stories about the company an impact score of 45.87 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of BTG?
Shares of BTG and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is BTG's stock price today?
One share of BTG stock can currently be purchased for approximately GBX 502.50.
How big of a company is BTG?
BTG has a market capitalization of £2.64 billion.
How can I contact BTG?
BTG's mailing address is 5 Fleet Place, LONDON, EC4M 7RD, United Kingdom. The company can be reached via phone at +44-20-75750000.
MarketBeat Community Rating for BTG (LON BTG)
MarketBeat's community ratings are surveys of what our community members think about BTG and other stocks. Vote "Outperform" if you believe BTG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTG will underperform the S&P 500 over the long term. You may vote once every thirty days.
